Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25

作者：Jain Prashi; Flaherty Patrick T^*; Yi Shuyan; Chopra Ishveen; Bleasdell Gwenyth; Lipay Josh; Ferandin Yoan; Meijer Laurent; Madura Jeffry D

来源：Bioorganic & Medicinal Chemistry, 2011, 19(1): 359-373.

DOI：10.1016/j.bmc.2010.11.022

• CDK5
• Cyclin dependent kinase
• Benzimidazole
• 1-Isopropyl benzimidazole

Alzheimer's disease (AD) is a progressive neurodegenerative disease resulting in cognitive and behavioral impairment. The two classic pathological hallmarks of AD include extraneuronal deposition of amyloid beta (A beta) and intraneuronal formation of neurofibrillary tangles (NFTs). NFTs contain hyperphosphorylated tau. Tau is the major microtubule-associated protein in neurons and stabilizes microtubules (MTs). Cyclin dependent kinase 5 (CDK5), when activated by the regulatory binding protein p25, phosphorylates tau at a number of proline-directed serine/threonine residues, resulting in formation of phosphorylated tau as paired helical filaments (PHFs) then in subsequent deposition of PHFs as NFTs. Beginning with the structure of Roscovitine, a moderately selective CDK5 inhibitor, we sought to conduct structural modifications to increase inhibitory potency of CDK5 and increase selectivity over a similar enzyme, cyclin dependent kinase 2 (CDK2). The design, synthesis, and testing of a series of 1-isopropyl-4-aminobenzyl-6-ether-linked benzimidazoles is presented.

• 出版日期2011-1-1